Inhibitors of tyrosine kinase 2 mediated signaling

US10508113B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Maria A. Argiriadi · Wayland, US
• Eric C. Breinlinger · Charlton, US
• Ellen Chien · Village of La Jolla, US
• Marlon D. Cowart · Round Lake Beach, US
• Kristine E. Frank · Portage, US
• Michael Friedman · Jerusalem, IL
• David J. Hardee · Vernon Hills, US
• J. Martin Herold · Cambridge, US
• Huaqing Liu · Buffalo Grove, US
• Wei Qiu · Boston, US
• Marc J. Scanio · Lindenhurst, US
• Michael R. Schrimpf · Grayslake, US
• Thomas R. Vargo · Stow, US
• Stacy A. Van Epps · Ashland, US
• Matthew P. Webster · Kenosha, US
• Andrew LITTLE · Sudbury, US
• Matthew H. Katcher · Brookline, US

Key dates

• Filing date: Mar 12, 2019
• Grant date: Dec 17, 2019
• Expiry date: Mar 12, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.